vTv Therapeutics to Present at Neuro Advance Boston

vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company committed to the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, announced today that company Chief Medical Officer, Dr. Larry Altstiel, MD, PhD, will speak on a panel at Neuro Advance Boston hosted by Harvard Medical School. Dr. Altstiel will participate on the panel “Novel Approaches to Alzheimer’s Disease,” from 9:30 to 10:10am on October 5th. Dr. Altstiel will focus on the novel mechanism of action behind vTv's lead investigational drug candidate called azeliragon, which is currently being studied in a Phase 3 trial for the treatment of mild Alzheimer’s disease.

Azeliragon is a novel orally active small-molecule antagonist of Receptor for Advanced Glycation Endproducts (“RAGE”). A broad range of human pathologic and experimental biologic investigation suggests that RAGE activation contributes to the pathogenesis of Alzheimer’s disease. Sustained interactions of Amyloid β and other mediators of inflammation with RAGE at the blood-brain barrier and in neuronal and microglial cells may play major roles in amyloid plaque formation, neuroinflammation, and chronic neural dysfunction – all hallmarks of Alzheimer’s disease.

The Phase 2b results of 5mg per day of azeliragon over a period of 18 months showed statistically significant benefits in mild-to-moderate Alzheimer’s patients (+3.1 points on ADAS-Cog11 standard measure of cognition) and greater benefit in mild patients (+4.0 points on ADAS-Cog11), with improvements on secondary endpoints including a significant reduction in psychiatric adverse events.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161003005286/en/

InvestorsIR@vtvtherapeutics.comorMediaNura Strong, 336-841-0300 X164PR@vtvtherapeutics.com

vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Mar 2024 to Apr 2024